The main pathways chosen to develop targeted or inhibitor molecules are those already known to be implicated in the GBM progression and radio/chemoresistance mechanisms, such as DNA damage repair (DDR) machinery, Notch, PI3-kinase/Akt/mTOR, JAK/STAT, and Wnt signalings [15]. The gene discussed is MTOR; the disease is glioblastoma.